Home > Insider Trading > Filing (0000899243-20-030831)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1701541	Black Diamond Therapeutics Inc.	BDTX	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1774690	Thomas Leggett	C/O Black Diamond Therapeutics, Inc. 139 Main Street Cambridge MA 02142	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-11-09	3,000	$10.86	3,000	No	4	M	Direct
Common Stock	Disposition	2020-11-09	3,000	$32.96	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-11-09	3,000	$0.00	3,000	$10.86

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
224,171		2029-09-08	No	4	M	Direct

Footnotes

Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 5, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.65 to $33.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
25% of the shares subject to this option vested and became exercisable on September 5, 2020, with the remainder vesting in 36 equal monthly installments thereafter.